Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov:51 Suppl 7:67-88.
doi: 10.1111/imj.15588.

Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021

Benjamin W Teh  1   2   3 , Daniel K Yeoh  2   3   4 , Gabrielle M Haeusler  1   2   3   5   6 , Costas K Yannakou  7 , Shaun Fleming  8 , Julian Lindsay  2   3   9 , Monica A Slavin  1   2   3   10 ; Australasian Antifungal Guidelines Steering Committee
Collaborators, Affiliations

Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021

Benjamin W Teh et al. Intern Med J. 2021 Nov.

Abstract

Antifungal prophylaxis can reduce morbidity and mortality from invasive fungal disease (IFD). However, its use needs to be optimised and appropriately targeted to patients at highest risk to derive the most benefit. In addition to established risks for IFD, considerable recent progress in the treatment of malignancies has resulted in the development of new 'at-risk' groups. The changing epidemiology of IFD and emergence of drug resistance continue to impact choice of prophylaxis, highlighting the importance of active surveillance and knowledge of local epidemiology. These guidelines aim to highlight emerging risk groups and review the evidence and limitations around new formulations of established agents and new antifungal drugs. It provides recommendations around use and choice of antifungal prophylaxis, discusses the potential impact of the changing epidemiology of IFD and emergence of drug resistance, and future directions for risk stratification to assist optimal management of highly vulnerable patients.

Keywords: Aspergillus; Candida; antifungal prophylaxis; haematological malignancy; stem cell transplantation.

PubMed Disclaimer

References

    1. Reinwald M, Silva JT, Mueller NJ, Fortun J, Garzoni C, de Fijter JW et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect 2018; 24(Suppl 2): S53-70.
    1. Teh BW, Tam CS, Handunnetti S, Worth LJ, Slavin MA. Infections in patients with chronic lymphocytic leukaemia: mitigating risk in the era of targeted therapies. Blood Rev 2018; 32: 499-507.
    1. Lindsay J, Teh BW, Micklethwaite K, Slavin M. Azole antifungals and new targeted therapies for hematological malignancy. Curr Opin Infect Dis 2019; 32: 538-45.
    1. Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 2018; 131: 121-30.
    1. Fleming S, Yannakou CK, Haeusler GM, Clark J, Grigg A, Heath CH et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J 2014; 44: 1283-97.

MeSH terms

Substances